Table 5.
Complications and clinical outcomes at data cutoff in patients with COVID-19
| Complications n (%) | All patients (n = 619) | Patients with increased leukocytes (n = 52) | Patients with non-increase leukocytes (n = 567) | P value |
|---|---|---|---|---|
| Any | 137 (22.1) | 38 (73.1) | 99 (17.5) | < 0.001 |
| Acute renal injury | 28 (4.5) | 9 (17.3) | 19 (3.4) | < 0.001 |
| Acute respiratory distress syndrome | 83 (13.4) | 24 (46.2) | 59 (10.4) | < 00.01 |
| Septic shock | 16 (2.6) | 5 (9.6) | 11(1.9) | 0.007 |
| Secondary infection | 46 (7.4) | 11 (21.2) | 35 (6.2) | 0.001 |
| Other viruses | 6 (1.0) | 1 (1.9) | 5 (0.9) | |
| Bacteria | 35 (5.7) | 7 (13.5) | 28 (1.9) | |
| Fungus | 5 (1.0) | 2 (3.8) | 3 (0.5) | |
| Clinical outcomes, n (%) | ||||
| Incidence of SIRS | 134 (21.6) | 35 (67.3) | 99 (17.5) | < 0.001 |
| Incidence of critically illness | 100 (16.1) | 26 (50.0) | 74 (13.1) | < 0.001 |
| Admission to ICU | 91 (14.7) | 24 (46.2) | 67 (11.8) | < 0.001 |
| Discharge from hospital | 451 (72.9) | 32 (61.5) | 419 (73.9) | 0.055 |
| Death | 43 (6.9) | 10 (19.2) | 33 (5.8) | 0.002 |
| Hospitalization | 125 (20.2) | 10 (19.2) | 115 (20.3) | 0.857 |
COVID-19 coronavirus disease 2019, ICU intensive care unit, SIRS systemic inflammatory response syndrome